Trials / Unknown
UnknownNCT04421391
QuadraMune(TM) for Prevention of COVID-19
Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Therapeutic Solutions International · Industry
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Accepted
Summary
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.
Detailed description
QuadraMune(TM) is composed of 4 natural ingredients. Pterostilbene is an analogue of resveratrol, and has been shown to possess antiinflammatory activity. Additionally, this compound suppresses macrophage activation while enhancing NK activity. Epigallocatechin gallate (EGCG) is one of the active ingredients in green tea and has been shown to act as an activator of T cells, and a suppressor of neutrophil mediated inflammation. Sulforaphane is derived from broccoli and studies have shown that it protects lungs from inflammatory pathology. Thymoquinone, which is chemically related to hydroxychloroquine, possessing antiviral effects and increases NK activity. QuadraMune is a combination of these ingredients and is believed to possess superior in vitro and in vivo therapeutic properties as compared to when the ingredients are administered individually. The study aims to assess preventative effects of QuadraMune(TM) administration for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | QuadraMune(TM) | QuadraMune(TM) is a commercially available nutritional supplement |
Timeline
- Start date
- 2020-06-08
- Primary completion
- 2020-11-01
- Completion
- 2020-11-08
- First posted
- 2020-06-09
- Last updated
- 2020-06-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04421391. Inclusion in this directory is not an endorsement.